Bristol-Myers dodges a bullet as PTAB turns down inter partes review pitch for Celgene's cash cow
Celgene just won another crucial patent skirmish in its ongoing fight to keep its blockbuster revenue pumping in from Revlimid — a key feature in the shaky $74 billion buyout deal that Bristol-Myers Squibb has been defending in a series of appearances over the last few days.
The Patent Trial and Appeal Board has denied a petition from Alvogen for an inter partes review of the Revlimid patents. That move comes a month after Dr. Reddy’s was also stiff armed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.